The Neuroscience Center is an approved site to administer SPRAVATO™ which was recently approved by the Food & Drug Administration as a treatment strategy for Treatment Resistant Depression (TRD). SPRAVATO™ is a type of ketamine, a medication that has been used for years to successfully alleviate the symptoms of TRD. The FDA’s approval of SPRAVATO™ acknowledges the important role that ketamine may have in treating TRD, a condition that impacts millions of people who do not respond to traditional monoaminergic antidepressants.
Because ketamine is classified by the FDA as a Schedule III drug, meaning there is some potential for dependency and abuse, SPRAVATO™ is only available through sites that enroll in a special program called a Risk Evaluation and Mitigation Strategy (REMS) program. TNC is enrolled as a REMS site and adheres to all the safety requirements.
The requirements for eligibility for SPRAVATO™ treatment include:
- A diagnosis of TRD.
- Past trials of two different anti-depressants that have not
resolved the symptoms.
- Currently taking an anti-depressant medication.
- Physical exam to rule out contra-indications for SPRAVATO.™
- Insurance preauthorization.
A typical course of SPRAVATO™ may include two treatments per week for one month, followed by one treatment per week for one month, followed by an ongoing pattern of treatments. In accordance with the SPRAVATO™ guidelines, please anticipate being in our clinic for at least two hours as the protocol requests monitoring of blood pressure and possible side effects such as sedation, dizziness, dissociation, or nausea. Due to these possible side effects, patients are required to have a safe ride home with a trusted friend or family member.
The Neuroscience Center has a long history of expertise in assessment, diagnosis, and treatment using ketamine-based therapies for Treatment Resistant Depression. Given our experience with ketamine and TRD, we have the knowledge, environment, medical, and psychological support to ensure a safe experience with this medication.
If you are interested in SPRAVATO™and would like to see if you qualify for the medication, please fill out our patient contact form and we will contact you for a free phone consultation.